Roche Holding AG (RHHBF) Research
Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets. The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions, cardiovascular and metabolic issues, ophthalmological ailments, and respiratory illnesses. Furthermore, its product portfolio extends to treatments for anemia, dermatological problems, hemophilia, inflammatory and autoimmune diseases, and conditions related to organ transplantation. Within its diagnostics business, Roche provides a range of in vitro tests designed for identifying various diseases, such as cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, among others. Complementing this, it also furnishes essential diagnostic instruments and chemical reagents. A significant research collaboration is in place with Synlogic, Inc., aimed at discovering a novel synthetic biotic treatment for inflammatory bowel disease (IBD).
Market snapshot
- Symbol
- RHHBF
- Price
- $410
- Day change
- +1.49%
- Market cap
- $254.6B
- P/E ratio
- 19.77x
- 52-week range
- 296.1-514.08
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Next earnings
- in 1 month
Recent news
- FDA approves first generic version of Roche's flu drug
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wednesday.
- Roche sticks to German investment after Eli Lilly cuts
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
- Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Peer companies
Open Roche Holding AG (RHHBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.